Human platelet concentrates treated with microbicidal 405 nm light retain hemostasis activity

Jackson, Joseph W. and Kaldhone, Pravin R. and Parunov, Leonid A. and Stewart, Caitlin F. and Anderson, John G. and MacGregor, Scott J. and Maclean, Michelle and Atreya, Chintamani D. (2024) Human platelet concentrates treated with microbicidal 405 nm light retain hemostasis activity. Journal of Photochemistry and Photobiology B: Biology, 255. p. 112922. 112922. ISSN 1011-1344 (https://doi.org/10.1016/j.jphotobiol.2024.112922)

[thumbnail of Jackson-etal-JPPBB-2024-Human-platelet-concentrates-treated-with-microbicidal]
Preview
 Text. Filename: Jackson-etal-JPPBB-2024-Human-platelet-concentrates-treated-with-microbicidal.pdf
Accepted Author Manuscript
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Chemical and UV light-based pathogen reduction technologies are currently in use for human platelet concentrates (PCs) to enhance safety from transfusion-transmitted infections. Relative to UV light, 405 nm violet-blue light in the visible spectrum is known to be less harmful. Hence, in this report for the first time, we have assessed the global hemostasis activity of PCs stored in plasma and the activities of six plasma coagulation factors (CFs) as a measure of in vitro hemostatic activity following exposure to the microbicidal 405 nm light. Apheresis PC samples collected from each screened human donor (n = 22) were used for testing of PCs and platelet poor plasma (PPP). Both PCs and PPPs were treated for 5 h with 405 nm light to achieve a previously established microbicidal light dose of 270 J/cm2. Activated partial thromboplastin time and prothrombin time-based potency assays using a coagulation analyzer and hemostatic capacity via Thromboelastography were analyzed. Thromboelastography analysis of the light-treated PCs and plasma present in the PCs showed little difference between the treated and untreated samples. Further, plasma present in the PCs during the light treatment demonstrated a better stability in potency assays for several coagulation factors compared to the plasma alone prepared from PCs first and subjected to the light treatment separately. Overall, PCs stored in plasma treated with 405 nm violet-blue light retain activity for hemostasis.

ORCID iDs

Jackson, Joseph W., Kaldhone, Pravin R., Parunov, Leonid A., Stewart, Caitlin F., Anderson, John G. ORCID logoORCID: https://orcid.org/0000-0003-4151-1619, MacGregor, Scott J. ORCID logoORCID: https://orcid.org/0000-0002-0808-585X, Maclean, Michelle ORCID logoORCID: https://orcid.org/0000-0001-5750-0397 and Atreya, Chintamani D.;

Persistent Identifier

https://doi.org/10.17868/strath.00089125
CORE (COnnecting REpositories)